Moreover, applying a powered longitudinal study design, especially for exploring intraindividual longitudinal changes in these biomarkers and also the confounding factors (including medications use and comorbidities), could further clarify the associations between levels of TRPV1, VIP, and PACAP and migraine progression or reversion, which needs additional studies in the future. This evidence concerns the gene VIP and migraine disorder.